phase ii trial of 1,4-dihydroxy-5,8-bis ( ( 2- ( ( 2-hydroxyethyl ) amino ) ethyl ) amino 9,10-anthracenedione dihydrochloride ) ( nsc 301739 , dhad ) in patients with metastatic malignant melanoma .
C0003174
anthracenedione
C0026259
dhad